Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Barbara Idzior-Waluś is active.

Publication


Featured researches published by Barbara Idzior-Waluś.


Metabolism-clinical and Experimental | 2016

The genetic spectrum of familial hypercholesterolemia in south-eastern Poland.

Mahtab Sharifi; Małgorzata Walus-Miarka; Barbara Idzior-Waluś; Maciej T. Malecki; Marek Sanak; Ros Whittall; Ka Wah Li; Marta Futema; Steve E. Humphries

Background Familial hypercholesterolemia (FH) is a common autosomal dominant disorder with a frequency of 1 in 200 to 500 in most European populations. Mutations in LDLR, APOB and PCSK9 genes are known to cause FH. In this study, we analyzed the genetic spectrum of the disease in the understudied Polish population. Materials and methods 161 unrelated subjects with a clinical diagnosis of FH from the south-eastern region of Poland were recruited. High resolution melt and direct sequencing of PCR products were used to screen 18 exons of LDLR, a region of exon 26 in the APOB gene and exon 7 of PCSK9. Multiplex ligation-dependent probe amplification (MLPA) was performed to detect gross deletions and insertions in LDLR. Genotypes of six LDL-C raising SNPs were used for a polygenic gene score calculation. Results We found 39 different pathogenic mutations in the LDLR gene with 10 of them being novel. 13 (8%) individuals carried the p.Arg3527Gln mutation in APOB, and overall the detection rate was 43.4%. Of the patients where no mutation could be found, 53 (84.1%) had a gene score in the top three quartiles of the healthy comparison group suggesting that they have a polygenic cause for their high cholesterol. Conclusions These results confirm the genetic heterogeneity of FH in Poland, which should be considered when designing a diagnostic strategy in the country. As in the UK, in the majority of patients where no mutation can be found, there is likely to be a polygenic cause of their high cholesterol level.


Medical Science Monitor | 2013

Nonalcoholic fatty liver disease is associated with low HDL cholesterol and coronary angioplasty in patients with type 2 diabetes

Aleksandra Trojak; Małgorzata Waluś-Miarka; Ewa Woźniakiewicz; Maciej T. Malecki; Barbara Idzior-Waluś

Background There is evidence that nonalcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. In this study we examined factors associated with the presence of NAFLD and the prevalence of macroangiopathy in patients with type 2 diabetes. Material/Methods Subjects were 101 consecutive patients with type 2 diabetes: 72 with NAFLD and 29 free of NAFLD. NAFLD was diagnosed by ultrasonography. Serum lipids were measured enzymatically and glycated hemoglobin HbA1c was measured by HPLC. Results The mean age of patients was 53.1±10.4 in the NAFLD group and 44.9±10.9 years in patients without NAFLD (p<0.001). The mean duration of diabetes was 10±6.3 years in patients with NAFLD and 15.1±7.8 years in those without NAFLD (p<0.001). Mean values of glycated hemoglobin A1c were similar in both groups. Patients with NAFLD were characterized by a significantly higher prevalence of coronary angioplasty (20.8% vs. 0%, p=0.008). Overweight and obesity were observed in a higher percentage of patients with NAFLD (p<0.001). Patients with NAFLD were characterized by significantly higher values of alanine transaminase (p=0.033), and lower serum concentrations of HDL-cholesterol (p<0.001) and creatinine (p=0.034). Logistic regression analysis (p<0.001) revealed that NAFLD was positively associated with waist circumference above normal (women >80 cm, men >94 cm) (p=0.0083) and alanine transaminase activity (p=0.0164), and negatively with creatinine concentration (p=0.0226). In a second logistic regression model (p<0.001), waist circumference (p<0.007) and total cholesterol (p<0.008) were positive predictors, while HDL-C (p<0.003) was a negative predictor of NAFLD. Conclusions The results of the study suggest that NAFLD is associated with visceral obesity and low HDL-cholesterol in patients with type 2 diabetes.


Kardiologia Polska | 2013

Intima–media thickness correlates with features of metabolic syndrome in young people with a clinical diagnosis of familial hypercholesterolaemia

Małgorzata Waluś-Miarka; Wiktoria Wojciechowska; Przemysław Miarka; Małgorzata Kloch-Badełek; Ewa Woźniakiewicz; Danuta Czarnecka; Marek Sanak; Maciej T. Malecki; Barbara Idzior-Waluś

BACKGROUND Familial hypercholesterolaemia (FH) is a monogenic lipid metabolism disorder characterised by markedly elevated serum low-density lipoprotein (LDL) cholesterol level due to a mutation in the LDL receptor gene. Clinical features of FH include premature atherosclerosis and coronary artery disease. AIM To explore associations between noninvasive markers of atherosclerosis including intima-media thickness (IMT) and pulse wave velocity (PWV) and blood lipids, blood pressure (BP) and obesity in a group of young patients with FH. METHODS Study population included 36 patients aged < 35 years with the diagnosis of FH based on the Simon Broome Register criteria, and their 49 relatives who comprised the control group free of FH. RESULTS Mean IMT values were higher in FH patients than controls (0.60 ± 0.19 vs. 0.53 ± 0.07 mm, respectively, p < 0.05).Mean body mass index (BMI) and waist circumference were similar in patients and controls. The prevalence of carotid atherosclerotic plaques was significantly higher among FH patients (n = 6) than in controls (n = 1) (21.4% vs. 2.6%, p = 0.012). Arterial hypertension was present in 27.8% of patients with FH and 16.3% of subjects in the control group. Systolic blood pressure (SBP) in FH patients correlated significantly with age (r = 0.35), BMI (r = 0.48) and waist circumference (r = 0.47), and diastolic blood pressure (DBP) correlated with BMI (r = 0.42) and waist circumference (r = 0.41). PWV correlated significantly with age (r = 0.44), SBP (r = 0.63) and DBP (r = 0.52). We did not find any correlations between IMT and serum lipids, BP or obesity indices in FH patients. CONCLUSIONS Our findings show a higher rate of arterial hypertension in young FH patients compared to their relatives free of FH, with significant associations between BP and indices of obesity and arterial stiffness. Intensive lipid lowering and antihypertensive therapy along with a reduction in central fat may be considered a mandatory treatment strategy in young FH patients to prevent atherosclerosis and increased arterial stiffness.


Journal of Clinical Lipidology | 2013

Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum

Andrzej Rynkiewicz; Barbara Cybulska; Maciej Banach; Krzysztof J. Filipiak; Tomasz J. Guzik; Barbara Idzior-Waluś; Jacek Imiela; Piotr Jankowski; Longina Kłosiewicz-Latoszek; Janusz Limon; Małgorzata Myśliwiec; Grzegorz Opolski; Andrzej Steciwko; Janina Stępińska; Tomasz Zdrojewski


International Journal of Cardiology | 2011

Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients

Małgorzata Waluś-Miarka; Barbara Katra; Danuta Fedak; Danuta Czarnecka; Przemysław Miarka; Ewa Woźniakiewicz; Maciej T. Malecki; Barbara Idzior-Waluś


Clinical and Experimental Nephrology | 2011

Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency

Przemysław Miarka; Barbara Idzior-Waluś; Marek Kuźniewski; Małgorzata Waluś-Miarka; Tomasz Klupa; Władysław Sułowicz


Atherosclerosis | 2006

Familial lecithin-cholesterol acyltransferase deficiency: Biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family

Barbara Idzior-Waluś; Jacek Sieradzki; Gert M. Kostner; Maciej T. Malecki; Tomasz Klupa; Teresa Wesołowska; Witold Rostworowski; Jadwiga Hartwich; Małgorzata Waluś; Aldona Dembińska Kieć; Marek Naruszewicz


Molecular Biology Reports | 2012

A novel mutation (Cys308Phe) of the LDL receptor gene in families from the South-Eastern part of Poland.

Małgorzata Waluś-Miarka; Marek Sanak; Barbara Idzior-Waluś; Przemysław Miarka; Przemysław Witek; Maciej T. Malecki; Danuta Czarnecka


Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine | 2015

Is now the time for probiotics in diabetes management

Barbara Idzior-Waluś; Małgorzata Waluś-Miarka


Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine | 2013

Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum.

Andrzej Rynkiewicz; Barbara Cybulska; Maciej Banach; Krzysztof J. Filipiak; Tomasz J. Guzik; Barbara Idzior-Waluś; Jacek Imiela; Piotr Jankowski; Longina Kłosiewicz-Latoszek; Janusz Limon; Małgorzata Myśliwiec; Grzegorz Opolski; Andrzej Steciwko; Janina Stępińska; Tomasz Zdrojewski

Collaboration


Dive into the Barbara Idzior-Waluś's collaboration.

Top Co-Authors

Avatar

Małgorzata Waluś-Miarka

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar

Maciej T. Malecki

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Danuta Czarnecka

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar

Marek Sanak

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anna Noczyńska

Wrocław Medical University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge